Efficacy of early referral to palliative care for improving quality of life and health care resources following recent diagnosis of advanced thoracic maglignancies.

niversity of Sydney0 个研究点目标入组 113 人开始时间: 2017年1月31日最近更新: 2022年10月24日

适应症

试验速览

暂无简介。

•1.Adults, aged 18 years and older, with a histological or cytological diagnosis within the last 60 days of either:
•(a)Advanced NSCLC (this includes de novo stage IV disease, recurrent NSCLC after definitive treatment, and locally advanced disease which is not planned for curative resection). Patients planned to receive curative intent chemoradiation for locally advanced disease are eligible or
•(b)Advanced SCLC (this includes extensive stage SCLC, recurrent SCLC after definitive treatment and locally advanced disease), or
•(c)Advanced MPM which is not planned for extrapleural pneumonectomy or pleurectomy-decortication.
•2.Australia-modified Karnofsky performance status of 50 to 100 at the time of randomisation (see Appendix 1).
•3.Willing and able to comply with all study requirements, including ability at the time of screening to complete the QOL questionnaires without assistance, in accordance with protocol requirements.
•4. Signed, written informed consent.

•1. Immediate referral to palliative care required, or already referred to palliative care (this
•includes referral to a community or hospital based palliative care service, or palliative care
•physician).
•2. Life expectancy of less than 3 months.
•3. Serious medical or psychiatric onditions that might limit the ability of the patient to comply with the protocol.

发起方